A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating
the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly
diagnosed higher-risk myelodysplastic syndromes (HR-MDS).